Is fecal microbiota transplantation a temporary patch for treatment of Clostridium difficile infection or a new frontier of therapeutics?

Research output: Contribution to journalEditorialpeer-review

7 Scopus citations
Original languageEnglish (US)
Pages (from-to)435-438
Number of pages4
JournalExpert Review of Gastroenterology and Hepatology
Issue number5
StatePublished - May 4 2018

Bibliographical note

Funding Information:
A. Khoruts has received research funding from Crestovo, a start-up company working to commercialize FMT. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Copyright 2018 Elsevier B.V., All rights reserved.


  • Clostridium difficile infection
  • fecal microbiota transplantation (FMT)
  • microbial community
  • microbiota therapeutics
  • regulation

Cite this